#1 Clinical Trials Search in Europe

Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Diagnostics

Go back

Diagnosing Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome (PAPA syndrome) can be challenging because there is no single test that confirms the condition, and its symptoms often resemble other diseases. This rare genetic disorder requires careful medical evaluation, family history analysis, and sometimes genetic testing to reach a proper diagnosis.

Introduction: Who Should Seek Diagnostic Testing

If you or your child experiences repeated episodes of painful joint swelling that look like an infection but don’t respond to antibiotics, it’s important to consider the possibility of PAPA syndrome and seek specialized medical evaluation. This condition typically begins in early childhood, with the first episode of arthritis (inflammation of the joints) occurring between 1 and 10 years of age, though the full picture of the disease may not become clear until later.[1]

Parents should be particularly alert if their child develops joint problems alongside unusual skin issues, especially if there’s a family history of similar symptoms. Because PAPA syndrome is inherited in an autosomal dominant pattern—meaning it can be passed from one parent to a child with a 50% chance—knowing your family’s medical history is crucial. If one parent carries the genetic mutation, other family members across generations may show at least some symptoms of the disease, even if they’re mild.[2]

Seeking early diagnosis is advisable because PAPA syndrome can lead to serious joint damage if left untreated. With repeated episodes, the joints can become permanently damaged, sometimes requiring multiple joint replacements. Early identification allows doctors to start appropriate treatment that may help preserve joint function and manage skin symptoms more effectively.[3]

⚠️ Important
PAPA syndrome is not infectious and cannot be spread from person to person through contact. Despite the name “pyogenic,” which suggests a bacterial cause, this condition is actually an inflammatory disorder caused by genetic changes that affect how the body’s immune system works. If your child has been diagnosed, there is no risk of spreading it to classmates or family members.[2]

Diagnostic Methods: How PAPA Syndrome Is Identified

Diagnosing PAPA syndrome requires a careful approach because no single test can definitively confirm the condition. Instead, doctors must piece together information from clinical symptoms, family history, laboratory tests, and sometimes genetic analysis to distinguish PAPA syndrome from other diseases that look similar.[4]

Clinical Evaluation and Physical Examination

The diagnostic process typically begins with a thorough medical examination and detailed discussion of symptoms. Doctors look for the characteristic pattern of the disease: recurrent episodes of arthritis that usually affect one joint at a time, with the joint becoming swollen, painful, and red. The clinical appearance often resembles septic arthritis—arthritis caused by bacteria in the joint—which can make initial diagnosis difficult. An important clue is that these episodes often occur after minor injuries to the joint, but they don’t improve with antibiotic treatment as bacterial infections would.[2]

A key diagnostic consideration is that not all three main symptoms—arthritis, pyoderma gangrenosum, and acne—appear at the same time or in every patient. The arthritis typically starts in childhood, while the skin problems tend to develop later, often during adolescence. This timing difference means that doctors may need to monitor a patient over time before making a confident diagnosis.[2]

Family History Assessment

Because PAPA syndrome is inherited, examining family history is an essential part of diagnosis. Since the condition follows an autosomal dominant pattern, doctors will ask detailed questions about whether other family members have experienced similar joint or skin problems. Often, more than one family member across different generations will show symptoms, though they may vary in severity. One parent usually shows at least some signs of the disease, even if they’re mild. This family pattern can be a strong indicator that points toward PAPA syndrome rather than other conditions.[2]

Joint Fluid Analysis

When a joint becomes swollen and inflamed, doctors may take a sample of fluid from inside the joint—a procedure called joint aspiration or arthrocentesis. In PAPA syndrome, this fluid appears purulent (cloudy and pus-like) and contains large numbers of neutrophils, which are white blood cells that fight infection. However, a crucial diagnostic finding is that when this fluid is tested for bacteria through cultures, the results are invariably negative—no bacteria grow. This combination of inflammatory fluid without infection is a hallmark of PAPA syndrome and helps distinguish it from true bacterial joint infections.[3]

Laboratory tests also typically show elevated leukocyte counts (white blood cells) in the synovial fluid, with neutrophils being the predominant cell type. The fact that this looks like an infection but isn’t caused by microorganisms is what makes PAPA syndrome so unusual and why it was historically misunderstood.[3]

Skin Biopsy

When patients develop skin lesions such as pyoderma gangrenosum or severe cystic acne, doctors may perform a skin biopsy—taking a small sample of affected skin tissue for examination under a microscope. In PAPA syndrome, these biopsies show prominent inflammation with a predominance of neutrophil white blood cells. In cases of pyoderma gangrenosum, the biopsy reveals superficial ulceration along with neutrophilic inflammation.[4]

The biopsy of joint tissue (synovial biopsy) similarly shows neutrophil accumulation without the presence of immunoglobulin or complement deposits that would suggest other types of inflammatory disease. While these findings aren’t specific to PAPA syndrome alone, they help rule out other conditions and support the diagnosis when combined with other clinical features.[2]

Genetic Testing

The most definitive way to confirm PAPA syndrome is through genetic testing. PAPA syndrome is caused by mutations in a gene called PSTPIP1 (proline-serine-threonine phosphatase interacting protein 1), which was previously known as CD2BP1. This gene was identified in 2002 on chromosome 15. The protein that this gene produces plays a role in regulating the body’s inflammatory response, and when mutated, it causes the excessive inflammation seen in PAPA syndrome.[2]

Interestingly, only two specific mutations in the PSTPIP1 gene account for most known cases of PAPA syndrome. Genetic testing, when available at specialized centers, can identify these mutations and provide a definitive diagnosis. This testing is particularly valuable because it can identify family members who carry the mutation before they develop symptoms, allowing for earlier monitoring and intervention.[3]

The PSTPIP1 protein has been shown to interact with another protein called pyrin (also known as marenostrin), which is encoded by the MEFV gene. Mutations in the MEFV gene cause a different condition called Familial Mediterranean Fever. Understanding these protein interactions helps researchers understand why PAPA syndrome causes the symptoms it does. The mutated PSTPIP1 protein in PAPA syndrome binds more strongly to pyrin than normal, which appears to trigger the inflammatory problems.[3]

Blood Tests and Inflammatory Markers

While not diagnostic on their own, various blood tests can support the diagnosis and help monitor disease activity. Patients with PAPA syndrome often show elevated markers of inflammation, including elevated C-reactive protein (CRP) and elevated levels of certain immune proteins. Blood tests may reveal elevated immunoglobulin G (IgG) and immunoglobulin A (IgA), as well as increased levels of substances like lipopolysaccharide-binding protein and matrix metalloproteinase-9.[5]

Elevated leukocyte counts with an increased percentage of neutrophils in the blood are also commonly seen. Elevated plasma neutrophil granule proteins and increased levels of inflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF) reflect the ongoing inflammation in the body. These tests help doctors assess the severity of inflammation and monitor how well treatments are working.[5]

Differential Diagnosis: Ruling Out Other Conditions

A critical part of diagnosing PAPA syndrome is distinguishing it from other conditions that can cause similar symptoms. The main conditions that doctors must rule out include juvenile idiopathic arthritis (a type of childhood arthritis), periodic fever syndromes, and bacterial infections. Because the arthritis in PAPA syndrome closely resembles septic arthritis, doctors must carefully exclude actual bacterial or other microbial infections through repeated negative culture results.[3]

The skin manifestations, particularly pyoderma gangrenosum, can also occur in other conditions such as inflammatory bowel disease or other autoinflammatory syndromes. The combination of sterile arthritis with these specific skin findings, especially in a family pattern, helps narrow the diagnosis to PAPA syndrome. Sometimes doctors must observe the patient over time and through multiple episodes before they can be confident in the diagnosis.[2]

Challenges in Diagnosis

PAPA syndrome is often diagnosed late because it’s so rare and its symptoms develop over time. The arthritis may appear years before skin problems become noticeable, and not all patients develop all three main symptoms. This variable presentation means that different specialists—rheumatologists, dermatologists, or pediatricians—may see the patient at different stages, each focusing on their area of expertise without initially recognizing the full syndrome.[1]

Additionally, the disease shows variable penetrance, meaning that even people who carry the genetic mutation may exhibit different symptoms or different severity of symptoms. Some individuals may have only very mild symptoms, which makes recognizing the family pattern more difficult. This variability is one reason why PAPA syndrome may be underdiagnosed and more common than currently estimated.[2]

⚠️ Important
A notable feature of PAPA syndrome is pathergy—the tendency for symptoms to develop or worsen after minor injuries. Patients may develop arthritis after small joint injuries or skin ulcers at sites where injections were given, surgical incisions were made, or even where intravenous lines were inserted. Recognizing this pattern is important for both diagnosis and prevention of complications during medical procedures.[4]

Diagnostics for Clinical Trial Qualification

When patients with PAPA syndrome are being considered for enrollment in clinical trials testing new treatments, they typically undergo a comprehensive set of diagnostic evaluations to confirm their diagnosis and establish baseline measurements of disease activity. These assessments serve as standard criteria for determining eligibility and for monitoring treatment responses during the trial.[3]

Genetic Confirmation

Clinical trials for PAPA syndrome typically require genetic confirmation of PSTPIP1 gene mutations as an entry criterion. This ensures that all participants truly have the condition being studied, which is essential for determining whether a treatment is effective. Genetic testing may be repeated or confirmed at specialized laboratories to ensure accuracy before enrollment.[2]

Baseline Disease Assessment

Before starting any experimental treatment, researchers need to thoroughly document the current state of the disease. This includes detailed joint examinations to identify which joints are affected, the degree of swelling and pain, and whether there’s already structural damage. Imaging studies such as X-rays or MRI scans may be performed to document baseline joint condition, which can later be compared to images taken during and after treatment to assess whether the therapy has prevented further damage.[1]

For skin manifestations, researchers may photograph lesions, measure their size and depth, and perform biopsies to establish the severity of inflammation. These baseline measurements provide objective data that can be compared to follow-up assessments to determine if a treatment is working.[4]

Laboratory Monitoring Panels

Clinical trials typically include comprehensive laboratory testing at baseline and at regular intervals throughout the study. This includes complete blood counts to measure white blood cell levels and percentages, inflammatory marker testing (such as CRP and other acute phase reactants), and measurement of specific cytokines like IL-1 and TNF that are thought to drive inflammation in PAPA syndrome.[5]

Since PAPA syndrome is an autoinflammatory condition, researchers may also measure levels of various immune proteins and inflammatory mediators to understand how the disease affects the immune system and how treatments change these patterns. Some studies have measured elevated neutrophil granule proteins and matrix metalloproteinase-9, which may serve as biomarkers of disease activity.[5]

Functional and Quality of Life Assessments

Beyond physical measurements, clinical trials often include standardized questionnaires and assessments that measure how PAPA syndrome affects daily life. These might include pain scales, mobility assessments, and quality of life surveys. For children, this may include assessments of how the disease affects school attendance, participation in activities, and social interactions.[2]

Understanding the full impact of the disease helps researchers evaluate whether new treatments not only reduce inflammation in laboratory tests but also meaningfully improve patients’ lives. This patient-centered approach ensures that treatments being tested address what matters most to people living with PAPA syndrome.[3]

Prognosis and Survival Rate

Prognosis

PAPA syndrome is described as a self-limiting disease, which means that symptoms often improve naturally over time, particularly as children grow older. The arthritis, which is typically the first symptom to appear in early childhood, tends to become less severe or may even subside by adolescence. However, by the time joint symptoms improve, skin problems often become more prominent, especially during the teenage years and beyond.[3]

Despite this self-limiting nature, PAPA syndrome can lead to serious complications if not properly managed. The most significant concern is joint destruction. Repeated episodes of sterile arthritis can cause permanent damage to articular cartilage (the smooth tissue covering the ends of bones in joints) and the bone tissue around the joint. Without appropriate treatment, some patients may require multiple joint replacements over their lifetime. However, with improved treatment options now available—particularly biological therapies that target specific inflammatory pathways—there is hope that joint damage can be limited in newly diagnosed cases.[3]

The severity and course of PAPA syndrome varies considerably from person to person, even within the same family. This variable expression means that some individuals carrying the genetic mutation may experience only mild symptoms, while others may have severe, debilitating disease. Additionally, the disease may show incomplete penetrance, meaning some people who carry the mutation may have very minimal symptoms or even remain nearly symptom-free. This variability makes it difficult to predict exactly how the disease will progress in any individual patient.[2]

The long-term outlook depends heavily on early diagnosis and appropriate treatment. Patients who receive effective anti-inflammatory treatment early in their disease course have a better chance of preserving joint function and minimizing skin complications. Regular follow-up with specialists who understand the condition is important for adjusting treatments as needed and preventing complications.[3]

Survival rate

PAPA syndrome itself is not typically life-threatening, and there is no specific survival rate data reported in the medical literature for this condition. The disease primarily affects joints and skin, and while it can cause significant disability and impact quality of life, it does not directly threaten survival. However, some less commonly associated features have been reported, including adult-onset insulin-dependent diabetes mellitus and proteinuria (protein in the urine), which may require additional medical management.[3]

The main health risks associated with PAPA syndrome relate to complications from severe inflammation, joint destruction requiring surgical interventions, and potential complications from the treatments themselves. Patients taking immunosuppressive medications to control inflammation may have increased susceptibility to infections, which requires careful monitoring. The overall life expectancy for people with PAPA syndrome is generally normal when the condition is properly managed with appropriate medical care.[2]

Ongoing Clinical Trials on Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome

References

https://pmc.ncbi.nlm.nih.gov/articles/PMC8362586/

https://www.printo.it/pediatric-rheumatology/GB/info/23/Papa-Syndrome-(Piogenic-Arthritis-Pioderma-Gancrenosum-and-Acne)

https://www.orpha.net/en/disease/detail/69126

https://dermnetnz.org/topics/papa-syndrome

https://omim.org/entry/604416

More information about
Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome:

FAQ

How do doctors distinguish PAPA syndrome from a bacterial joint infection?

Doctors distinguish PAPA syndrome from bacterial infection by analyzing fluid from the affected joint. While both conditions cause joints to become swollen, painful, and filled with pus-like fluid containing neutrophils, PAPA syndrome is characterized by consistently negative bacterial cultures—no bacteria grow when the fluid is tested. Additionally, PAPA syndrome doesn’t respond to antibiotic treatment, tends to recur, and often occurs in patients with a family history of similar symptoms.[2]

Can genetic testing predict how severe PAPA syndrome will be?

Genetic testing can confirm whether someone has a PSTPIP1 mutation that causes PAPA syndrome, but it cannot accurately predict how severe symptoms will be. The disease shows variable penetrance and expression, meaning people with the same genetic mutation can have very different experiences—from mild symptoms to severe disease. Some family members may carry the mutation but have only minimal symptoms.[2]

Why do symptoms of PAPA syndrome change with age?

PAPA syndrome typically follows a pattern where arthritis appears first in early childhood, often between ages 1 and 10, and then tends to improve or subside by adolescence. Meanwhile, skin problems like pyoderma gangrenosum and severe cystic acne become more prominent starting around puberty and may persist into adulthood. The biological reasons for this age-related shift in symptoms are not fully understood, but it reflects how the disease naturally evolves over time.[2]

Is there a blood test that can diagnose PAPA syndrome?

There is no single blood test that can diagnose PAPA syndrome on its own. However, blood tests showing elevated inflammatory markers (like C-reactive protein), increased white blood cells with high neutrophil percentages, and elevated levels of certain immune proteins can support the diagnosis. Genetic blood testing to identify PSTPIP1 gene mutations provides the most definitive confirmation, but this requires specialized testing not available at all facilities.[3]

Should I be tested for PAPA syndrome if my parent has it?

If your parent has PAPA syndrome, you have a 50% chance of inheriting the genetic mutation because the condition follows an autosomal dominant pattern. Whether to undergo genetic testing is a personal decision that should be discussed with a genetic counselor. Testing can identify the mutation before symptoms appear, allowing for earlier monitoring and potentially earlier treatment if symptoms develop. However, some people prefer not to know, especially since symptoms may be mild or absent even with the mutation.[2]

🎯 Key takeaways

  • • PAPA syndrome cannot be diagnosed with a single test—doctors must combine clinical observations, family history, joint fluid analysis, skin biopsies, and genetic testing to reach a diagnosis.
  • • The hallmark diagnostic finding is sterile arthritis: joint fluid that looks infected with lots of neutrophils but grows no bacteria on culture testing.
  • • Genetic testing for PSTPIP1 mutations provides definitive confirmation but may not be immediately available at all medical centers.
  • • Family history is crucial—PAPA syndrome follows an autosomal dominant pattern, so examining multiple generations can provide important diagnostic clues.
  • • Pathergy (development or worsening of symptoms after minor injuries) is an important diagnostic clue that helps distinguish PAPA syndrome from other conditions.
  • • The timing of symptoms matters—arthritis typically appears first in early childhood (ages 1-10), while skin problems become prominent during adolescence.
  • • Not all patients have all three symptoms (arthritis, pyoderma gangrenosum, and acne) at the same time, making diagnosis challenging and sometimes delayed.
  • • Early diagnosis is important because repeated episodes of untreated arthritis can cause permanent joint damage requiring multiple replacements.

Connected medications: